Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 08/30 09:13:31 am
78 CHF   +0.19%
08/29 GLAXOSMITHKLINE : Ahmed - GSK Has Full Confidence in the Nigerian Ec..
08/29 AHMED : GSK Has Full Confidence in the Nigerian Economy
08/29 NOVARTIS : convenes experts to discuss new technologies in healthcar..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS AG
08/29 GLAXOSMITHKLINE : Ahmed - GSK Has Full Confidence in the Nigerian Economy
08/29 AHMED : GSK Has Full Confidence in the Nigerian Economy
08/29 NOVARTIS : convenes experts to discuss new technologies in healthcare at Interna..
08/27 Stada shareholder AOC pushes through board reshuffle
08/27 LEPLEY REELS IN TOP HONOURS FOR NOVA : Tony Burman catches up with the angling a..
08/26 NOVARTIS AG (NYSE : NVS) Announces Positive Phase III Results For MS Drug
08/26 NOVARTIS : Alcon Research Assigned Patent
08/25 NOVARTIS' : phase III MS study successfully meets endpoints
08/25 NOVARTIS : announces positive phase III results showing efficacy of BAF312 in pa..
08/24 NOVARTIS AG (NYSE : NVS) Licenses LGT209 To Cyon Therapeutics, Inc., Teams Up Wi..
More news
Sector news : Pharmaceuticals - NEC
08:49aDJBusiness Watch -- WSJ
08/29 Mylan to launch generic EpiPen at half the price of original
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/29DJROCHE : Receives US FDA Emergency Use Authorization for Zika Test -- Update
08/29DJROCHE : Receives US FDA Emergency Use Authorization for Zika Test
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/29 CTI Bio's late-stage study of lead product candidate pacritinib shows mixed r..
08/28 Momenta Has Momentum After Recent Patent Decision
08/25 Siponimod Rides To Novartis' Rescue
08/25 Teva Holds Cracking Door On Copaxone Generics
08/25 Novartis' BAF312 successful in late-stage multiple sclerosis study
Advertisement
Financials ($)
Sales 2016 48 839 M
EBIT 2016 11 354 M
Net income 2016 7 849 M
Debt 2016 14 751 M
Yield 2016 3,56%
P/E ratio 2016 23,54
P/E ratio 2017 21,17
EV / Sales 2016 4,58x
EV / Sales 2017 4,45x
Capitalization 208 887 M
More Financials
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 89,5 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-10.83%208 887
JOHNSON & JOHNSON16.74%328 086
PFIZER INC.8.77%212 965
ROCHE HOLDING LTD.-12.84%212 954
MERCK & CO., INC.19.29%174 236
ASTRAZENECA PLC7.33%173 471
More Results